AI Cancer Surveillance Startup BIOS Life Raises $25M Seed

A new player has emerged in the fight against cancer, aiming to revolutionize patient monitoring with an AI-driven platform. BIOS Life has successfully closed a $25 million seed funding round, signaling strong investor confidence in its vision for personalized cancer surveillance. The company is building an intelligent operating system designed to continuously track individuals at high risk for cancer and those who have already overcome the disease.

The substantial seed investment was led by Triple Point Ventures, with significant participation from Redmile Group, VSquared Ventures, and Kindred Capital. This capital infusion will fuel the development and deployment of BIOS Life's innovative approach, which moves beyond generic, age-based screening protocols. The current standard of care often fails to account for individual biological nuances, leaving significant gaps in detection, particularly for cancer survivors and those with a heightened genetic predisposition.

Leading the charge at BIOS Life are seasoned industry veterans. Ryan Richardson, formerly Chief Strategy Officer at BioNTech and Chairman of its AI subsidiary InstaDeep, serves as CEO. He is joined by Zach Taylor, another BioNTech alumnus, as COO. The medical expertise is anchored by Dr. Logan Frank, a board-certified radiologist and former Director of Breast Radiology at the University of Missouri, who holds the Chief Medical Officer role. The technical backbone is further strengthened by Geoff Hyde, who previously held leadership positions at One Medical and Galileo, overseeing product and engineering, and Thomas Pierrot, who led InstaDeep’s genomics AI research, now heading BIOS Life's AI initiatives.

BIOS Life's core offering is a sophisticated platform that synthesizes genomic, clinical, and lifestyle data to create a dynamic "digital twin" of an individual's health. This evolving model is coupled with a dedicated virtual care team, enabling proactive and continuous surveillance. The company is launching two initial programs: one tailored for individuals with elevated cancer risk and another focused on the critical ongoing monitoring needs of cancer survivors. This personalized strategy addresses a significant unmet need, as an estimated 40 million individuals in the U.S. fall into these categories, often underserved by current healthcare frameworks.

The company's technological advantage is bolstered by its commercial rights to InstaDeep’s Nucleotide Transformer, a leading genomics foundation model. Furthermore, BIOS Life has established a strategic, multi-year alliance with Tempus, including its hereditary testing arm, Ambry Genetics. This partnership will provide access to extensive de-identified oncology data, crucial for training and validating the platform's predictive algorithms. The platform is slated for a U.S. launch in the latter half of 2026, with a waitlist now open.

The market for cancer screening and survivorship is substantial, with current methods often generalized. BIOS Life's focus on individual biology taps into a growing demand for precision medicine. The company's strategic positioning, leveraging deep connections within the BioNTech, InstaDeep, and Tempus ecosystems, provides a strong foundation for rapid development and market penetration. This funding round underscores the potential for AI to transform preventative healthcare and chronic disease management, particularly in complex areas like oncology.